# China NMPA Drug Inspection - Donghu Community Health Service Station, Hedong Subdistrict Office - Licorice tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/donghu-community-health-service-station-hedong-subdistrict-office/31b7731d-61a3-4acc-8105-3f809110ccdf/
Source feed: China

> China NMPA drug inspection for Donghu Community Health Service Station, Hedong Subdistrict Office published December 23, 2021. Drug: Licorice tablets. The Hebei Provincial Drug Administration issued a quality bulletin on December 23, 2021, detailing failures discovered d

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hebei Province Drug Quality Bulletin (2021 Drug Supervision and Sampling Inspection No. 4)
- Company Name: Donghu Community Health Service Station, Hedong Subdistrict Office
- Publication Date: 2021-12-23
- Drug Name: Licorice tablets
- Inspection Finding: The [content determination] item did not meet the requirements.
- Action Taken: Control measures such as sealing and seizure shall be taken in accordance with the law; a case shall be filed for investigation and necessary risk control measures shall be taken, and the results of the handling shall be made public within three months.
- Summary: The Hebei Provincial Drug Administration issued a quality bulletin on December 23, 2021, detailing failures discovered during its annual sampling and inspection program. The report identifies Anguo Jiuwang Pharmaceutical Co., Ltd. as having produced substandard licorice tablets (Batch No. 20122607). Testing conducted by the Hengshui Comprehensive Inspection and Testing Center confirmed that these products failed the 'content determination' requirement, indicating that the active ingredient levels did not meet established quality standards. Samples were collected from retail and community healthcare providers, including Zhong Sheng Tai Pharmacy and the Donghu Community Health Service Station. Governed by the Drug Administration Law of the People's Republic of China, the regulatory framework mandates immediate corrective and punitive measures. Authorities have already moved to seize and seal the non-compliant batches to prevent further distribution. Required actions include the formal investigation and prosecution of the manufacturer for producing substandard drugs, the implementation of risk control protocols, and the public disclosure of final enforcement results within three months. Additionally, any evidence of counterfeit activity must be referred to the public security department for criminal prosecution. These efforts ensure the integrity of the pharmaceutical supply chain and protect public health through strict regulatory oversight.

Company: https://www.globalkeysolutions.net/companies/donghu-community-health-service-station-hedong-subdistrict-office/d0cb0e6c-a5f4-42ba-9fd3-82062c4bc76f/